{"id":147,"date":"2024-02-21T12:12:28","date_gmt":"2024-02-21T10:12:28","guid":{"rendered":"https:\/\/webs.uab.cat\/therCNS\/?page_id=147"},"modified":"2026-04-13T11:48:51","modified_gmt":"2026-04-13T09:48:51","slug":"projects-last-5-years-m","status":"publish","type":"page","link":"https:\/\/webs.uab.cat\/therCNS\/projects-last-5-years-m\/","title":{"rendered":"Financed Projects, Recognitions & Awards"},"content":{"rendered":"\n

Active financed projects<\/mark><\/h2>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Gene strategy therapy for GNB1 in patient-derived neurons<\/strong>
Funding Entity: Fundaci\u00f3n Universidad Aut\u00f3noma de Madrid (C\u00e1tedra UAM \u2013 Merck de Innovaci\u00f3n en Ciencia y Salud)
Time: 3 years, from: 01\/10\/2026 – 31\/12\/2027.
Principal Investigator: Laura Rodr\u00edguez Estevez<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Evaluation of the efficacy of a gene strategy therapy for GNB1 in patient-derived neurons<\/strong>
Funding Entity: GNB1 International Foundation
Time: 3 years, from: 01\/01\/2026 – 30\/06\/2026.
Principal Investigator: Miguel Chill\u00f3n<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

NEUROAGE: Innovaci\u00f3 en Envelliment Saludable i Malalties Neurodegeneratives<\/strong>
Funding Entity: Xarxes d’R+D+I d’AGAUR. 2025 XARDI 00006
Time: 3 years, from: 01\/01\/2026 – 31\/12\/2028.
Coordinator: VHIR. Principal Investigator of the group: Miguel Chill\u00f3n<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

MLC Advanced Gene therapy: Next-step Evaluation and Translation (MAGNET).<\/strong>
Funding Entity: European Leukodystrophy Association, ELA 2025-004C2
Time: 2 years, from: 01\/01\/2026 – 31\/12\/2027.
Coordinator: Assumpcio Bosch. Collaborator: Miguel Chill\u00f3n<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Cornerstone for developing next-generation drugs for healthy aging<\/strong>
Funding Entity: Ag\u00e8ncia de Gesti\u00f3 d’Ajuts Universitaris i Recerca (AGAUR). 2025 INNOV 00057
Time: 18 months, from: 01\/10\/2025 – 31\/03\/2027.
Principal Investigator: Miguel Chill\u00f3n<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Towards an effective and safe therapy for hormonal-deficiency osteoporosis based on klotho protein<\/strong>
Funding Entity: Fundaci\u00f3 Institut de Recerca HUVH. VHIR-FIT-2025-005
Time: 1 year, from: 05\/06\/2025 – 04\/06\/2026.
Principal Investigator: Joan Roig Soriano<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Unraveling the effects of the rejuvenating protein HEBE in the pathological complexity of Alzheimer\u2019s disease: dissecting amyloid beta composition, myelin sheath\u2019s oxidation profiles and reactive oxygen species distribution.<\/strong>
Funding Entity: ALBA Synchrotron (Standard academic programme. FEDER funds)
Time: 6 months, from: 01\/07\/25 to: 31\/12\/25.
Principal Investigator: David Ramirez-Gomez.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Development of a gene therapy strat<\/strong>egy for GNB1 Encephalopathy<\/strong>.
Funding Entity: Asociaci\u00f3n “GNB1 Espa\u00f1a”.
Time: 4 years, from: 01\/07\/25 to: 30\/06\/29.
Principal Investigator: M. Chill\u00f3n.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

TERAV+<\/strong>
Funding Entity: ISCIII. REDES DE INVESTIGACI\u00d3N COOPERATIVA ORIENTADAS A RESULTADOS EN SALUD (RICORS). RD24\/0014\/0039
Time: 3 years, from: 01\/01\/25 to: 31\/12\/27.
Principal Investigator: Coordinador:Manel Joan (IDIBAPS). IP: Miguel Chillon<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Bringing Klotho protein as a new therapy against age-associated muscle degeneration<\/strong>
Funding Entity: Fundaci\u00f3 Institut de Recerca HUVH. VHIR-FIT-24-002
Time: 1 year, from: 13\/12\/2024 to: 12\/12\/2025.
Principal Investigator: Joan Roig Soriano<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Towards an effective and safe therapy for hormonal-deficiency osteoporosis based on klotho protein<\/strong>
Funding Entity: CaixaImpulse Innovation 2024. La Caixa. (CI24-20581)
Time: 2 years, from: 15\/10\/24 to: 14\/10\/26.
Principal Investigator: J. Roig.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Chemistry, manufacturing and controls (CMC) regulatory challenges of viral-vector based gene therapy medicinal products (GTMPS) focused on rare neurodiseases<\/strong>
Funding Entity: Ag\u00e8ncia de Gesti\u00f3 d’Ajuts Universitaris i Recerca (AGAUR). 2024-DI00052
Time: 3 years, from: 01\/08\/24 to: 31\/07\/27.
Principal Investigator (UAB): M. Chill\u00f3n.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

The European Rare Diseases Research Alliance (ERDERA).<\/strong>
Funding Entity: Horizon Europe. European Union.
Time: 4 years, from: 01\/09\/24 to: 31\/08\/28.
Principal Investigator (Gene Therapy at VHIR): M. Chill\u00f3n.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Use of chimeric chronokines for neurodegenerative diseases and cognitive impairments associated with aging<\/strong>
Funding Entity: Fundaci\u00f3 Institut de Recerca HUVH. VHIR-PHD-2023-007
Time: 4 years, from: 01\/02\/2024 – 30\/01\/2028.
Principal Investigator: Miguel Chillon<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Therapeutical modulation of the microglia-neuronal interaction by chronokines to treat chronic brain inflammation associated with aging. (\u03bc\u22124-WELL-AGING).<\/strong>
Funding Entity: Proyectos de Generaci\u00f3n de Conocimiento. Ministerio de Ciencia e Innovaci\u00f3n. (PID2022-142624OB-I00).
Time: 3 years, from: 01\/09\/23 to: 31\/08\/26.
Principal Investigators: B. Almolda & M. Chill\u00f3n. <\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Development of a gene therapy strategy for ADSL Deficiency.<\/strong>
Funding Entity: Fundaci\u00f3n ANTIAN (CB619758).
Time: 3 years, from: 01\/01\/24 to: 31\/12\/26.
Principal Investigator: M. Chill\u00f3n.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Advanced Therapies.<\/strong>
Funding Entity: ISCIII. Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS). RD21\/0017\/0008.
Time: 3 years, from: 01\/01\/22 to: 31\/12\/25.
Coordinator: Jose M Moraleda (FFIS); Principal Investigator: M. Chill\u00f3n.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Development of a gene therapy strategy<\/strong><\/strong> for SPG52.<\/strong>
Funding Entity: Asociaci\u00f3n “La lucha de Abril”.
Time: 6 years, from: 01\/02\/20 to: 31\/01\/26.
Principal Investigator: M. Chill\u00f3n.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Development of a gene therapy strat<\/strong>egy for GNB1 Encephalopathy<\/strong>.
Funding Entity: Asociaci\u00f3n “Gen Rebelde”.
Time: 8 years, from: 01\/04\/21 to: 31\/03\/29.
Principal Investigator: M. Chill\u00f3n.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n\n\n\n

Recognitions & Awards<\/mark><\/h2>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Transference Award UAB-2018 to M. Chillon<\/strong>
by the Universitat Aut\u00f2noma de Barcelona Catalunya.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Excellence Research Groups, Generalitat de Catalunya<\/strong>.<\/strong>
2021 SGR-00529
2017 SGR-01468
2014 SGR-01354
2009 SGR-01300
2005 SGR-00169
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

TECNIO Quality Accreditation by ACCIO (Generalitat de Catalunya). <\/strong> 2019<\/strong>: 15\/03\/2019 to 26\/02\/2025. 2025<\/strong>: 27\/02\/2025 to 29\/12\/2028
<\/strong>It certifies the high quality standards of services and procedures of the UPV.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

ISO International Standards Certification by AENOR and IQNet . 23\/08\/2018.
<\/strong>This certifies the implementation of guidelines, policies and processes in compliance with the ISO 9001:2015 quality standards.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n\n\n\n

Completed projects (Last 5 years)<\/mark><\/h2>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Spanish Adenovirus Network: From basic Biology to Nanobiomedicine.<\/strong>
Funding Entity: MICINN: Acciones de dinamizaci\u00f3n “Redes de Excelencia” (RED2022-134221-T).
Time: 2 years, from: 01\/06\/23 to: 31\/05\/25.
Coordinator: Carmen San Martin (CSIC); Principal Investigator: M. Chill\u00f3n.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Study and development of the first technological platform to assay adeno-associated viruses for gene therapy treatments<\/strong>.
Funding Entity: ISCIII y CDTI. CONVOCATORIA proyectos de i+d+i vinculados a la medicina personalizada y terapias avanzadas. PMPTA22\/00048
Time: 2 years, from: 01\/01\/23 to: 30\/06\/25.
Coordinator: company Kymos; Principal Investigator: M. Chill\u00f3n.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Personalized gene therapy for MECP2 using CRISPR\/Cas9 technology together with AAV administration in 3D cell cultures and Kl mice.<\/strong>
Funding Entity: European Joint Programme-Rare Diseases and ISC-III EJP RD JTC 2020. AC20\/00051.
Time: 3 years, from: 01\/01\/21 to: 31\/10\/24.
Coordinator: I. Meloni (Unisi, IT); Principal Investigator: M. Chill\u00f3n.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Study of the effects of the chronokine Klotho in maintenance of myelin sheaths in a non-human primate model of aging<\/strong>.
Funding Entity: ALBA Synchrotron (Standard academic programme. FEDER funds)
Time: 6 months, from: 01\/07\/23 to: 31\/12\/23.
Principal Investigator: B. Almolda.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

TECNIO: Vector Production Unit (UPV)<\/strong>.
Funding Entity: ACCIO, Generalitat Catalunya
Time: 1 year, from: 01\/01\/23 to: 31\/12\/23.
Principal Investigator: M. Chill\u00f3n.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Personalized Platform to analyze antiepileptics drugs.<\/strong>
Funding Entity: AGAUR. Modalitat A. Llavor Ind\u00fastria del Coneixement.
Time: 1 year, from: 01\/10\/22 to: 30\/09\/23.
Principal Investigator: M. Chill\u00f3n.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Recombinant HEBE: A chimeric Chronokine to rejuvenate the Brain<\/strong>.
Funding Entity: Programa Proof of Concept. Convocatoria 2020
Time: 1 year, from: 01\/04\/21 to: 31\/03\/22.
Principal Investigator: J.F. espinosa.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Vector Production Unit<\/strong> (UPV): Personnel for Technical Support (PTA).<\/strong>
Funding Entity: Ministerio de Ciencia e Innovaci\u00f3n: PTA2019-017896-I.
Time: 3 years, from: 01\/09\/20 to: 30\/08\/23.
Principal Investigator: M. Chill\u00f3n.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Molecular and functional characterization of new recombinant chimeric chronokines. Implications for cognitive decline associated with aging.<\/strong>
Funding Entity: Ministerio Ciencia Innovaci\u00f3n. Proyectos I+D+i Retos Sociedad. PID2019-104034RB-I00.
Time: 3 years, from: 01\/06\/20 to: 31\/05\/23.
Principal Investigator: M. Chill\u00f3n.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Development of new gene therapies based on inteins.<\/strong>
Funding Entity: Ministerio Ciencia Innovaci\u00f3n. Retos Colaboraci\u00f3n. RTC2019006879-1.
Time: 3 years, from: 01\/01\/20 to: 30\/06\/22.
Coordinator: Proteodesign. Principal Investigator: M. Chill\u00f3n.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

An innovative therapy for SARS-CoV2 based on circle RNAs (CIRCO-3).<\/strong>
Funding Entity: Fundaci\u00f3n Santander
Time: 2 years, from: 01\/06\/20 to: 31\/05\/22.
Coordinator: Juana D\u00edez (UPF). Principal Investigator: M. Chill\u00f3n.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Development of a gene therapy strategy to treat the genetic forms of the Nephrotic Syndrome (AAV-Crb2).<\/strong>
Funding Entity: Ministerio Ciencia Innovaci\u00f3n. Convocatoria CERVERA 2020: IDI-20200258
Time: 2 years, from: 01\/05\/20 to: 30\/04\/22.
Coordinator: Company Ninevah Therapeutics. Principal Investigator: M. Chill\u00f3n.
<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Industrial Doctorate with<\/strong> Regi Jofre.<\/strong>
Funding Entity: AGAUR; 2018-DI-066.
Time: 4 years, from: 01\/01\/19 to: 31\/12\/22.
Principal Investigators: M. Chillon, A. Bosch, E. Rosell.
<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Active financed projects Gene strategy therapy for GNB1 in patient-derived neuronsFunding Entity: Fundaci\u00f3n Universidad Aut\u00f3noma de Madrid (C\u00e1tedra UAM \u2013 Merck de Innovaci\u00f3n en Ciencia y Salud)Time: 3 years, from: 01\/10\/2026 – 31\/12\/2027.Principal Investigator: Laura Rodr\u00edguez Estevez Evaluation of the efficacy of a gene strategy therapy for GNB1 in patient-derived neuronsFunding Entity: GNB1 International FoundationTime: […]<\/p>\n","protected":false},"author":2848,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-147","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages\/147","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/users\/2848"}],"replies":[{"embeddable":true,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/comments?post=147"}],"version-history":[{"count":98,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages\/147\/revisions"}],"predecessor-version":[{"id":1359,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages\/147\/revisions\/1359"}],"wp:attachment":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/media?parent=147"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}